DEPAKOTE CP

LOE Approaching

divalproex sodium

Abbott
NDAORALTABLET, DELAYED RELEASE
Approved
Jul 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
12

Mechanism of Action

tract. The mechanisms by which valproate exerts its therapeutic effects have not been established. It has been suggested that its activity in epilepsy is related to increased brain concentrations of gamma-aminobutyric acid (GABA).

Indications (12)

acute manicmixed episodes associated with bipolar disorderwithwithout psychotic featuresmigraine headacheswomenwomen of childbearing potentialmigraineEpilepsybipolar disorderwomen with epilepsyplan to become pregnant unless other medications have failed to provide adequate symptom control

Clinical Trials (5)

NCT00579280Phase 4Completed

Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD

Started Jul 2007
224 enrolled
Bipolar DisorderPanic DisorderGeneralized Anxiety Disorder
NCT00974012Phase 1Completed

Divalproex Sodium 500 mg Extended Release Tablets Under Non-Fasting Conditions

Started Oct 2006
24 enrolled
Healthy
NCT00864006Phase 1Completed

Bioequivalence Study of Divalproex Sodium 125 MG Delayed Release Tablets Under Fasting Conditions

Started Oct 2006
28 enrolled
Seizures
NCT00974441Phase 1Completed

Divalproex Sodium 500 mg Extended Release Tablets Under Fasting Conditions

Started Aug 2006
48 enrolled
Healthy
NCT00306475Phase 4Completed

Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?

Started Mar 2006
60 enrolled
SchizophreniaSchizoaffective Disorder
Company
Abbott
Abbott
ABBOTT PARK, IL
1916 open jobs
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers